Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Presents New Assays and Clinical Chemistry Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 14 Nov 2022

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its new assays to determine HDL and LDL-cholesterol, alongside the respons®940, the new member of the company’s family of clinical chemistry analyzers, at MEDICA 2022. More...

The MEDICA 2022 Trade Fair is being held in Düsseldorf, Germany from 14-17th November. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At this year’s edition of MEDICA, DiaSys is exhibiting respons®910, a compact and fully-automated bench top clinical chemistry analyzer designed for maximum efficiency. Its high on-board capacity of 30 different methods in mono- or twin-containers and 30 sample positions offer the necessary flexibility for everyday use. The integrated STAT port allows easy loading of emergency samples at any time. The wide range of high-quality clinical chemistry and immunoturbidimetric tests manufactured by DiaSys rounds off the respons®910 system.

DiaSys is also presenting the HDL-c direct FS and LDL-c direct FS, its two innovative new reagents added to its cardiovascular risk assessment portfolio. Both are homogenous assays for direct determination and offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

Another highlight at the company’s booth at MEDICA 2022 is the presentation of Procalcitonin FS, an innovative, immunoturbidimetric assay to determine Procalcitonin that offers an excellent alternative to established methods. Procalcitonin FS offers a reliable alternative, when time matters in sepsis management. The fluid-stable, particle enhanced immunoturbidimetric assay is characterized by a good precision at clinical cut-off levels and high prozone security. Procalcitonin FS has good onboard and calibration stability and shows high tolerance to endogenous interferents and common therapeutics used in sepsis management. Additionally, the assay shows good concordance to established methods. Procalcitonin FS, dedicated kits are available for the DiaSys respons® systems and BioMajesty® JCA-BM6010/C.

Related Links:
DiaSys Diagnostic Systems


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.